Keyphrases
Panaxynol
100%
Resilience
100%
Colitis
100%
Microbiome
27%
Microbial Metabolites
27%
Natural Products
18%
Ablation Strategy
18%
Gut Microbiome
18%
Off-target Effects
9%
Intestinal Barrier Function
9%
Host Immune Response
9%
Beneficial Effects
9%
Treg
9%
Mechanistic Approach
9%
Immune Profile
9%
Goblet Cells
9%
Immune Ablation
9%
Mucosal Immunity
9%
Immune Signature
9%
SAFE Strategy
9%
Immune Profiling
9%
Disease Initiation
9%
Microbial Omics
9%
Primary Intention
9%
Strategy Evaluation
9%
Bloody Stool
9%
American Ginseng
9%
Inflammatory Bowel Disease
9%
Female Mice
9%
Mucus
9%
Diarrhea
9%
Drug Lead
9%
Crypt Distortion
9%
Gut Metabolites
9%
Metabolic Profiling
9%
Microbial Signatures
9%
Intestinal Barrier
9%
Colon Cancer
9%
Mouse Model
9%
Increased Vulnerability
9%
Professional Development Training
9%
Gut Health
9%
Immunosuppression
9%
Quality of Life
9%
Endoscopic Score
9%
Intestinal Inflammation
9%
Bioactive Components
9%
Antibiotics
9%
Large Intestine
9%
Massive Weight Loss
9%
Corticosteroids
9%
Disease Severity
9%
Clinical Outcomes
9%
Metabolic Signature
9%
Disease Progression
9%
Male Mice
9%
Effective Strategies
9%
Medicine and Dentistry
Gut
100%
Colitis
100%
Panaxynol
100%
Immunity
63%
Metabolite
45%
Microbiome
45%
Intestinal Mucosal Barrier
18%
Gut Microbiome
18%
Disease Severity
9%
Goblet Cell
9%
Rectal Bleeding
9%
Ginseng
9%
Tioxolone
9%
Diarrhea
9%
Tamsulosin
9%
Side Effect
9%
Large Intestine
9%
Immunosuppressive Treatment
9%
Mucosal Immunity
9%
Mucus
9%
Natural Product
9%
Enteritis
9%
Quality of Life
9%
Mediator
9%
Colon Carcinoma
9%
Inflammatory Bowel Disease
9%
Diseases
9%
Antibiotics
9%
Pharmacology, Toxicology and Pharmaceutical Science
Colitis
100%
Panaxynol
100%
Microbiome
63%
Diarrhea
9%
Inflammatory Bowel Disease
9%
Enteritis
9%
Tamsulosin
9%
Side Effect
9%
Natural Product
9%
Rectum Hemorrhage
9%
Tioxolone
9%
Panax quinquefolius
9%
Disease Severity
9%
Mouse Model
9%
Colon Carcinoma
9%
Antibiotics
9%
Diseases
9%